Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Aprea Therapeutics

07/08/2026 16:48

Aprea Therapeutics Inc APRE.OQ APRE.O is expected to  show a rise in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026
The Doylestown Pennsylvania-based  company is expected to report revenue of $168.67 thousand, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Aprea Therapeutics Inc is for a loss of 23 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Aprea Therapeutics Inc is $5.00, about 690.5% above its last closing price of $0.63
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.23
-0.23
-0.22
Beat
4.3
Dec. 31 2026
-0.39
-0.39
-0.32
Beat
17.9
Sep. 30 2025
-0.11
-0.34
-0.47
Missed
-38.8​
Jun. 30 2025
-0.73
-0.74
-0.53
Beat
28.9
​​
Dec. 31 2024
-0.69
-0.49
Beat
28.6​
Sep. 30 2024
-0.68
-0.74
-0.64
Beat
14.1
Jun. 30 2024
-0.61
-0.63
-0.58
Beat
8.7
This summary was machine generated August 7 at 15:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)